Andrew Denver - CochLear Non-Executive Director
| CHEOY Stock | USD 103.45 1.34 1.28% |
Director
Mr. Andrew Leslie Denver, BSc, MBA, FAICD, is NonExecutive Director of Cochlear Limited since February 1, 2007. He was Chairman of Universal Biosensor Pty Limited, Director of CathRx Limited, Anzon Australia Limited and Principals Funds Management Pty Limited. He was former Managing Director of Memtec Limited and President Asia for Pall Corporationrationration. He is Fellow of the Australian Institute of Company Directors. He holds a BS degree in Chemistry from the University of Manchester and a Masters of Business Administration from Harvard University. He is Member of the Human Resources Committee Member of the Audit Committee Member of the Nomination Committee Member of the Medical Science Committee and Chairman of the Technology and Innovation Committee. since 2007.
| Age | 68 |
| Tenure | 17 years |
| Professional Marks | MBA |
| Phone | 61 2 9428 6555 |
| Web | https://www.cochlear.com |
CochLear Management Efficiency
The company has return on total asset (ROA) of 0.0973 % which means that it generated a profit of $0.0973 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1713 %, meaning that it generated $0.1713 on every $100 dollars invested by stockholders. CochLear's management efficiency ratios could be used to measure how well CochLear manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Quentin Blackford | Axogen Inc | 39 | |
| Randall Hogan | Medtronic PLC | 64 | |
| Mark Gold | Axogen Inc | 69 | |
| Scott Donnelly | Medtronic PLC | 59 | |
| Mike Donovan | Axogen Inc | 53 | |
| Susan Harnett | Paragon 28 | 57 | |
| Samuel Riccitelli | Orthopediatrics Corp | 59 | |
| Carl Florio | Paragon 28 | 64 | |
| Pamela Bailey | Integer Holdings Corp | 72 | |
| Francesco Bianchi | LivaNova PLC | 60 | |
| Mark Foley | Glaukos Corp | 55 | |
| Austin Adams | Paragon 28 | 71 | |
| Fred Hite | Orthopediatrics Corp | 56 | |
| Dirk Kuyper | CONMED | 61 | |
| Stefano Gianotti | LivaNova PLC | 53 | |
| Sharon OKane | LivaNova PLC | 49 | |
| Joseph Mandato | Axogen Inc | 70 | |
| Denise OLeary | Medtronic PLC | 62 | |
| Lisa Colleran | Axogen Inc | 59 | |
| Guido Neels | Axogen Inc | 69 | |
| Marc Stapley | Glaukos Corp | 50 | |
Management Performance
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0973 |
CochLear ADR Leadership Team
Elected by the shareholders, the CochLear's board of directors comprises two types of representatives: CochLear inside directors who are chosen from within the company, and outside directors, selected externally and held independent of CochLear. The board's role is to monitor CochLear's management team and ensure that shareholders' interests are well served. CochLear's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, CochLear's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Glen Boreham, Non-Executive Independent Director | ||
| Greg Bodkin, Senior Vice President - Supply Chain & Operational Excellence | ||
| Jan Janssen, Senior Vice President - Design and Development | ||
| Yasmin Allen, Non-Executive Director | ||
| Rom Mendel, President Acoustics | ||
| Jennifer Stevenson, VP Brand | ||
| Kristina Devon, VP Relations | ||
| Piers Shervington, Senior Corporate Communications Manager, Investor Relations Contact Officer | ||
| Lisa Aubert, Pres America | ||
| Christopher Smith, President - Americas Region | ||
| Katharine McLennan, Senior Vice President - People and Culture | ||
| Rick HollidaySmith, Non-Executive Chairman of the Board | ||
| Anthony Bishop, President - Asia Pacific | ||
| Dig Howitt, COO | ||
| Alison Deans, Non-Executive Independent Director | ||
| Brent Cubis, CFO | ||
| Donal ODwyer, Non-Executive Director | ||
| Edward Byrne, Non-Executive Director | ||
| Richard Toselli, Chief Medical Officer | ||
| Stuart Sayers, President - Services | ||
| Neville Mitchell, CFO, Company Secretary | ||
| Richard Brook, President - European Region | ||
| Dean Phizacklea, Senior Vice President Global Marketing | ||
| Amanda Lampe, Senior Vice President - Corporate Affairs, Strategic Alignment & Public Health | ||
| Jennifer Hornery, Senior Vice President - People & Culture | ||
| Richard MBA, Pres EMEA | ||
| Jan Eng, Chief Officer | ||
| Ray Jarman, Company Secretary | ||
| Andrew Denver, Non-Executive Director | ||
| Shah Hussain, Non-Executive Independent Director | ||
| Tony Manna, President Americas Region | ||
| David Hackshall, Chief Officer | ||
| MBA BE, MD, CEO | ||
| Diggory Howitt, President Executive Director | ||
| Bruce Robinson, Independent Non-Executive Director | ||
| David Cade, Chief Medical Officer |
CochLear Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is CochLear a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.17 | |||
| Return On Asset | 0.0973 | |||
| Profit Margin | 0.18 % | |||
| Operating Margin | 0.23 % | |||
| Current Valuation | 9.05 B | |||
| Shares Outstanding | 131.56 M | |||
| Price To Earning | 49.26 X | |||
| Price To Book | 8.15 X | |||
| Price To Sales | 5.55 X | |||
| Revenue | 1.65 B |
Pair Trading with CochLear
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if CochLear position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in CochLear will appreciate offsetting losses from the drop in the long position's value.Moving together with CochLear Pink Sheet
| 0.8 | SYK | Stryker Earnings Call This Week | PairCorr |
| 0.65 | BSX | Boston Scientific Corp Buyout Trend | PairCorr |
| 0.7 | SEMHF | Siemens Healthineers | PairCorr |
The ability to find closely correlated positions to CochLear could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace CochLear when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back CochLear - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling CochLear Ltd ADR to buy it.
The correlation of CochLear is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as CochLear moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if CochLear ADR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for CochLear can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in CochLear Ltd ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in persons. You can also try the Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
Complementary Tools for CochLear Pink Sheet analysis
When running CochLear's price analysis, check to measure CochLear's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy CochLear is operating at the current time. Most of CochLear's value examination focuses on studying past and present price action to predict the probability of CochLear's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move CochLear's price. Additionally, you may evaluate how the addition of CochLear to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |